Virafin Virafin gets emergency nod. DBT-BIRAC supported | UPSC PIB NEWS
Virafin
Virafin gets emergency nod.
DBT-BIRAC supported ‘Virafin’ from Zydus Cadila gets emergency nod for treating moderate COVID-19 infections in adults.
The restricted emergency use approval was given by the Drug Controller General of India (DCGI).
Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the patient in the early stages of infection, resulted in their faster recovery.
For the development of Virafin, Zydus appreciated the support provided by DBT-BIRAC COVID 19 Research Consortium through NBM, for conducting the Phase II human clinical trial studies.
The studies confirmed the safety, tolerability and efficacy of Virafin.
The studies also reported that Virafin reduces viral load and aids in managing the disease in a better way, such as reduction in the need for supplemental oxygen, thereby reducing the respiratory tension caused due to low oxygen levels.
Phase III clinical trial studies reported that a larger proportion of patients when administered subcutaneously with Virafin turned out to be RT-PCR negative by day 7, apart from faster recovery as compared to other antiviral agents.
#GS3
Join-- @UPSC_PIB_NEWS
